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1. Introduction 
The co-existence of immunodeficiency and autoimmunity called as “old couple” is known 
from the clinics, but the background and mechanism responsible for this phenomenon is far 
from explanation. The both; immunodeficiency and autoimmune diseases belong to group 
of rare diseases. The population of children with immunodeficiency of humoral immunity 
demonstrating clinical symptoms of deficiency is small and only a part of them develops 
autoimmune disease which means these patients are really very small group. Because of low 
number of such patients there is a lack of standards of diagnostic procedures and 
therapeutic approach.  
The clinical observations and analysis of co-existence of these  two different 
pathomechanisms lead to questions –  
1. why, in diseases with impaired function of immune system, the antibodies and 
autoantibodies are produced,   
2. why the prolonged inflammation develops leading to tissue and organ damage,  
3. why these autoimmune diseases are different in clinical features, course and response 
to therapy,  
4. why we are not able to find the factors helping in selection of patients with high risk of 
autoimmune disease within immunodeficiency group.  
The develop of autoimmune diseases is a result of many factors occurring in sequence or at 
the same time what seems to be the puzzle with hundreds of pieces. In the immune 
deficiency some of these pieces are missed at the beginning but despite this the puzzle is 
fulfilled and the autoimmunity develops. It is why, this phenomenon is still fascinating….  
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2. The role of antibodies in pathomechanism of celiac and inflammatory 
bowel diseases 
2.1. The production of autoantibodies 
The autoantibodies are produced by B-1 subpopulation of B lymphocytes, plasma cells 
localized in lymph nodes and bone marrow, similarly to production of specific antibodies to 
pathogens; bacterial, viral or parasitic. They react with autoantigens e.g. determinants, 
receptors present on cell surface, products of cells (e.g. hormones, cytokines, insulin, 
enzymes), nuclei, DNA and organelles released after cells death. In healthy people the 
autoantibodies (e.g. antinuclear, rheumatoid factor) are noted in the serum in low titer what 
is probably an effect of persist low affinity self-reacting T and B lymphocytes in the thymus 
and bone marrow. The increase of occurrence and amount of  autoantibodies with age in the 
healthy people is supporting the view that this small population of self-reactive 
lymphocytes is present during whole life [1].  
The induction of autoantibodies production is not fully elucidated and the hypothesis about 
trigger by chronic inflammation, molecular mimicry with microbial antigens, aberrant 
expression of HLA-DR on cell surface as facilitating factor, are postulated. In systemic 
autoimmune diseases like lupus the antigens are intracellular so the above  suggestions are 
not very suitable. The possible explanations of anti-DNA antibodies production includes the 
process of apoptosis and formation of nucleosomes containing pure DNA. It is highly 
probable, that dying cells e.g. within inflammatory infiltrations of tissues release many 
different organelles, proteins and enzymes induce production of antibodies to them. The 
antibodies against structure of nucleus (e.g. histones, centromers, centriols, nucleoli), Golgi 
apparatus, mitochondria, peroxidase, specific proteins (e.g. Scl-70, RNP), enzymes are 
associated with different types of autoimmune diseases. Delayed clearing of dying cells and 
abundance, stability, resistance to degradation of some nucleoproteins are stimulating the 
immune response through activation of Toll-like receptors. This hypothesis might apply to 
some of systemic autoimmune diseases [1]. 
The presence of autoantibodies in high titer is generally associated with damage of target 
cells or organs and occurrence of clinical symptoms of disease. The deposits of immune 
complexes (autoantibodies – antigens – complement) in the vessels or located directly in the 
tissue expressing the autoantigen are injurious for the surrounding tissue. These complexes 
bind the complement, activate the cascade, stimulate the production of pro-inflammatory 
cytokines, chemotactic factors for infiltrating cells leading to support of autoantibodies 
production and amplification of the inflammation (self-perpetuating inflammatory process). 
In animal models this damaging effect of autoantibodies and immune complexes was 
showed for systemic autoimmune diseases. In celiac disease,  the anti transglutaminase 
antibodies are associated with reduction of intestinal epithelial cells endocytosis, 
differentiation and proliferation. In general, they lead to decrease of intestinal/epithelial 
barrier function. The studies demonstrated the reduction of the epithelial cells adhesion in 
experimental model with CaCo cell line and anti-transglutaminase antibodies implicated the 
role of these antibodies in pathogenesis of celiac disease. In histology of mucous membrane 
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from  patients with untreated celiac disease, the epithelium tends to blister or totally detach 
from the basement membrane. The antibodies  mediated inhibition of epithelial cells 
adhesion might be an explanation for the detachment [2]. The mechanism of tissue damage 
and role of autoantibodies in IBD (Leśniowski-Crohn’s disease and ulcerative colitis) are not 
fully described [3-5]. 
3. Primary deficiency of humoral immunity 
3.1. Isolated IgA deficiency (IgAD)  
IgAD is the most common immunodeficiency of humoral immunity. The frequency of this 
deficiency is variable in different regions e.g. 1:400 in Finland, 1:600 in USA and 1:15000 
children in Japan. The environmental factors, diet and food type, climate are suggested as 
explanation for this wide range of IgAD frequency [6-8]. The diagnosis of IgAD is based on 
low level (often below detection) of IgA, normal or compensatory high level of IgG, normal 
level of  IgM in child older than 4 years of life.  In this defect the majority of affected 
children (70-80%) is asymptomatic [6,7]. The remaining (20-30%) IgAD patients suffer from 
recurrent infections, allergies and autoimmune diseases. The respiratory and 
gastrointestinal tract are mainly involved. Recurrent infections of upper respiratory tract 
caused by different bacterias, often encapsulated  are noted in younger children, the 
prolonged sinusitis is typical for older children and teenagers. Within IgAD patients the 
incidence of allergies is 20 times higher then in healthy population. The asthma, allergic 
rhinitis, conjunctivitis, food allergy, atopic dermatitis and urticaria are common. The 
autoimmunity is represented by hematological symptoms e.g. thrombocytopenia, 
neutropenia, hemolytic anemia and gastrointestinal disease like celiac disease, IBD. In adults 
with IgAD the lupus erythematodes, rheumatoid arthritis, thyroid diseases and chronic 
active hepatitis are noted [6,9-12]. In gastrointestinal tract, besides the autoimmune chronic 
inflammatory disease, the infestation with Giardia lamblia, bacterial infections, nodular 
hyperplasia are very often observed within IgAD patients [6,12]. The occurrence of clinical 
symptoms like abdominal pain, discomfort, diarrhea, constipation is 10-20 times higher 
within IgAD than within healthy children. The most probable explanation is deficient 
production of secretory IgA [9,13].  
The pathogenesis of IgAD is based on defective terminal maturation of B cells into IgA 
secreting plasma cells leading to reduced level of serum and secretory (mucosal) IgA [13]. 
The IgA exists in both monomeric and polymeric (mainly dimeric) forms. In humans two 
subclasses are distinguished – IgA1 and IgA2. The dimeric IgA is formed with joining (J)-
chain. The secretory IgA (sIgA) is produced locally within lymphoid tissue under the 
mucous membrane and released at the luminal surface of jejunum [14]. sIgA composed of 
IgA2 molecules characterizes high resistance to enzymatic digestion by bacterial proteases. 
This immunoglobulin plays an important role in protection of mucous membranes lining 
the gastrointestinal, respiratory and urinary tracts from pathogens present within the 
lumen. It is the first line of defense against microorganisms based on agglutinating activity 
and facilitating the clearance of pathogens [12]. The role of sIgA in selection of antigens 
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entering through the mucous membrane is also postulated. Functions of sIgA include direct 
neutralization of pathogens, intracellular neutralization of viruses during transepithelial 
transport and inhibition of receptors mediated activation of immune system [12]. The lack of 
sIgA is compensated by IgG and IgM [12]. The chronic inflammatory diseases as celiac 
disease, Leśniowski-Crohn’s disease, ulcerative colitis are only a part of gastrointestinal 
symptoms seen in IgAD patients. The other causes of clinical symptoms (abdominal pain, 
discomfort, constipation or diarrhea) include bacterial infections e.g. Helicobacter pylori, 
Campylobacter jejuni (preferentially in adults) and parasitic Giardia lamblia infestation. In 
jejunum biopsy the type of mucosal damage, villous flattening are suggesting celiac disease. 
After therapy eliminating Giardia lamblia the damage of mucous is repaired, however, in 
some cases this damage may be irreversible. The deep mucous damage difficult to repair is 
also an effect of the prolonged infection and diarrhea. sIgA is necessary for clearance of 
jejunum surface from e.g. parasites, bacterias and yeasts so the lack of this immunoglobulin 
facilitates attachment and proliferation of the organism on the surface of intestinal 
epithelium [6,9,11,12,15].   
The frequency of Leśniowski-Crohn’s disease, ulcerative colitis (mainly in adults) is not well 
recognized in IgAD [13,16]. Moreover, in adult patients with IgAD and gastrointestinal 
symptoms the nodular lymphoid hyperplasia (NLH) is observed and diagnosed as a 
separate clinical entity. In histology, the nodules contain the large amount of IgM-bearing 
cells. There are found in lamina propria, superficially in submucosa of small intestine, 
occasionally in large bowel, rectum  or stomach. Massive occurrence of these nodules and/or 
large size are associated with malabsorption, flattening of villi and with obstruction in some 
cases [16]. The differential diagnosis of Leśniowski-Crohn’s disease, nodular lymphoid 
hypertrophy (NLH) or celiac disease is difficult because the clinical symptoms and 
histological changes are overlapping.  
3.2. Common variable immunodeficiency (CVID) 
The common variable immunodeficiency is a heterogeneous disease with the frequency of 
1:25000 to 1:66000 diagnosed first in adults. Following this, the description of clinical 
features and course of disease was based on observations of adult patients. CVID is 
diagnosed after exclusion all other known causes of hypogammaglobulinemia in adults and 
in children older than 4 years of life. The criteria of CVID include hypogammaglobulinemia 
(IgG only or IgG and IgA, IgM), low production of specific antibodies in response to 
vaccination and, in reasonable amount of patients, disorders of cellular response e.g. low 
number of T cells, reverse CD4:CD8 ratio, low response of T lymphocytes to stimulation in 
vitro [7,12,17-20]. The hypogammaglobulinemia is a result of deregulation of B-cell 
differentiation process and disturbances of T-cell regulatory function [18]. Impaired T-cell 
function (e.g. proliferation) and signaling have also been reported, including abnormalities 
in expression and function of T cell receptor. Number of B lymphocytes in peripheral blood 
and in lymph nodes are within normal range usually but the amount of plasma cells is 
diminished. However, in 12% of CVID patients the number of B lymphocytes in peripheral 
blood is below detection level [21]. Analysis of B cell subpopulation showed the reduction of 
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memory B cells (CD19+CD27+IgD-) number in majority of CVID patients. The reduction of 
memory B cells is associated with more severe clinical course of CVID (e.g. splenomegaly, 
bronchiectases, autoimmunity). Up to now, it is the one and only parameter with predictive 
value for the clinical course of CVID [22,23]. However, the reduction of memory B cells did 
not correlate with genetic mutation described in CVID patients [17]. In subset of CVID 
patients (5-10%) mutation in TACI (transmembrane activator and calcium-modulator) gene 
was discovered. TACI is a member of TNF-like receptor family involved in transduction of 
signals associated with cell survival, apoptosis and isotype switching. The ligands for TACI 
expressed on peripheral B cells include BAFF (B-cell activating factor) and APRIL (a 
proliferation-inducing ligand) both in TNF ligand family expressed on monocytes and 
dendritic cells. BAFF and APRIL can induce isotype switching but in the absence of TACI 
(their receptor) plasma cell maturation and immunoglobulins production is inhibited [18]. 
The heterogeneity of clinical features noted within CVID patients might resembled defects 
like TACI deficiency, BAFF deficiency, APRIL deficiency, loss of inducible co-stimulator and 
others diagnosed as one disease although named “variable” [18].  
The observations of CVID in children showed the difference between these patients and 
adults in clinical symptoms and course of disease [24]. Within patients diagnosed as adults, 
the chronic sinusitis, bronchiectases, chronic lung disease are more common than in CVID 
diagnosed in childhood (Table 1). The level of IgG (before substitution) is not predictive for 
type, severity and clinical course of infections [21,28].  The bacterial cultures showed 
Haemophilus influenzae, Streptococcus pyogenes, Staphylococcus aureus and Streptococcus 
pneumoniae in european population of CVID patients [16,25-26]. Moreover, the susceptibility 
of CVID patients to specific type of microorganism is noted so Ureaplasma uraelyticum, 
Mycoplasma (different species), enteroviruses are leading to infections and destructive 
chances of organs (e.g. fibrotic process in bladder). Despite the cumulating data about 
deficiencies of humoral immunity, the diagnosis of CVID is delayed 6 to 8 years an average, 
what lead to sequelae of recurrent infections e.g. lung fibrosis, bronchiectases, chronic 
sinusitis, underweight, inhibition of growth, anemia [20-21,25-27]. In a large study of 248 
CVID patients (children and adults) the severe and recurrent infections, mostly in 
respiratory system, were noted in 90% of patients [19]. The chronic lung disease was noted 
in 27% of adult patients. The recurrent infections of lower respiratory tract may be 
associated with the bronchiectases. However, the bronchiectases often are a consequence of 
few but severe lung infections. In children, the chronic lung disease and bronchiectases are 
rare and seen in group of teenagers (the time of disease seemed to be an important factor). 
Moreover, in children with CVID the lymphoid interstitial pneumonia (LIP); unusual and 
rare type of lung disease is seen. In our group of 52 children with CVID  the histology of 
lung biopsy showed LIP in 2 patients (boy and girl). In both cases the prolonged therapy 
with steroids was effective but adverse reactions to steroids limited this therapy. The lung 
fibrosis was slowed down although still progressing what lead to respiratory insufficiency 
despite of regular IgG substitution [personal observations]. The chronic sinusitis, LIP or 
bronchiectases are developing independently to regular substitution of IgG, even in higher 
dose [28].  
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Table 1. The differences between CVID in adults and children 
The autoimmunity is associated with CVID in about 20-30% of patients and the 
hematological symptoms are most common [10,16,17,19,21,29-34]. The dysregulation of 
immune system in CVID seemed to be paradoxical; while antibody production in response 
to pathogens and vaccines is impaired, at the same time the production autoantibodies 
might be excessive [32]. In large study of 311 adult patients with CVID the autoimmunity 
was diagnosed in 37% (116 patients). The cytopenias were noted in 55 patients including 
thrombocytopenia (41 patients), hemolytic anemia (17 patients) and neutropenia (10 
patients) [30]. The slightly lower percentage of autoimmunity (22%) was noted within other 
studied group of  248 CVID adult patients but the thrombocytopenia was most frequent 
[19,32]. In reasonable number of patients the autoimmune symptoms preceded the diagnosis 
of CVID [17,19,21,34].  
The autoimmune/inflammatory diseases of gastrointestinal tract (IBD) including Leśniowski-
Crohn’s disease, celiac disease, pernicious anemia, autoimmune liver disease, ulcerative 
colitis and nodular lymphoid hyperplasia (NLH) are the second group of complications 
(coexisting symptoms/diseases) noted in 20-50% of CVID patients [9,13,16,18-19,21,28-29,34-
36]. The clinical symptoms of IBD in CVID are similar to patients without CVID but often 
more discrete, milder and unspecific. In children  unspecific abdominal pain, weight loss and 
inhibition of growth are prominent. The typical symptoms like diarrhea, constipation and 
dyspepsia, disturbances of jejunum motility, weakness are present too but they could be often 
neglected and explained by school stress, problems of diet, life style and maturation. In both 
groups of CVID patients the results of malabsorption are observed [13,16,19]. 
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The diagnosis of autoimmune diseases is based on presence of antibodies and 
autoantibodies in serum. In CVID there are two problems: low production of specific 
antibodies as a marker of immune system dysfunction and lack of antibodies of given 
immunoglobulin class e.g. IgA in cases of CVID with IgA deficiency. The second problem is 
associated with histology of tissues involved in autoimmune process. The disturbances of B 
cell ontogeny seen as abnormal maturation, impaired somatic hypermutation and lack of 
memory B cell are associated with different histology of jejunum in IBD in CVID [13,36]. In 
biopsy of jejunum mucous of patients with celiac or Leśniowski-Crohn’s disease the low 
number, even lack of B cells and plasma cells in infiltrations are observed. This atypical 
pattern of infiltrating cells in CVID became a reason for named the celiac disease as celiac-
like, similar – Crohn’s-like instead Crohn’s disease [13,37]. 
3.3. Substitution of immunoglobulins in CVID 
The main goal of regular substitution of immunoglobulin IgG (intravenous or 
subcutaneous) in CVID is replacing the specific antibodies. These antibodies produced by 
healthy blood donors after vaccinations and contact with common pathogens prevent the 
infections with spectrum of common pathogens. The dose for substitution is wide (0.4 - 0.8 
g/kg body weight) with the suggestion for higher dose in first period of IgG substitution to 
obtained patient’s stabilization (“steady-state”). After 6-8 months of regular substitution, the 
maintaining dose is usually about 0.4 g/kg body weight. The half-life of IgG is 21-24 days 
indicating intravenous infusion of IgG (IVIG) in every 3-4 weeks [16-17,20,28,38-40]. The 
modifications of dose are possible in two ways – higher (or lower) dose for singular infusion 
and shorter (or longer) distance between infusions. The bacterial infections, wounds healing 
after injuries or surgery are consuming immunoglobulins so higher dose of IgG is 
recommended. Moreover, the individual variations in half-life of administered IgG, shorter 
half-time in patients with chronic lung disease or gastrointestinal disease need the 
modifications of IVIG substitution (patient-tailored), precise monitoring of IgG level and 
clinical status of patient [20]. The purpose of substitution is to prevent infections, at least, to 
decrease their frequency and moderate their clinical course. Moreover, the regular 
substitution of IgG in replacing dose is effective in some autoimmune disease like chronic 
thrombocytopenia, chronic neutropenia [16]. This effect is probably associated with anti 
inflammatory activity of IgG, although the precise mechanisms are not described. The 
different mechanisms responsible for anti-inflammatory activity on IgG preparation are 
defined for the high dose of immunoglobulins used in autoimmune diseases. It might be 
that; the regularity, long time of substitution and accumulation of small repeated effects are 
responsible for anti-inflammatory activity of IVIG in low dose, similar to anti-inflammatory 
effects of IVIG high dose (1.0-2.0 g/kg b.w.) [20,38]. The adverse reactions of IVIG occurred 
immediately during the infusion or after up to 4 days. They are mild or sever including 
anaphylactic shock [16,41]. Most often the fever, chills, pain (headache, abdominal pain) are 
noted in children during the infusion. The most severe, late reactions are the consequence of 
tissue distribution of immunoglobulin particularly into central nervous system. Heavy and 
progressive headache, vomiting, disturbances of vision, speech and balance keeping are 
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typical. The therapy with intensive hydration and steroids given intravenously are usually 
effective. In a case of  occurrence of severe adverse reactions the subcutaneous (SCIG) form 
of substitution is recommended. The amount of immunoglobulins given monthly is divided 
in four portions (0.1 g/kg of body weight per week) administered with special pomp. The 
effectiveness is similar to intravenous substitution, the adverse reaction are very rare and 
limited to the place of injection. SCIG is form of home therapy very comfortable for patients, 
offering the independence from the hospital.  
3.4. Antibiotics in prophylaxis of infections   
In part of children with CVID the effect of IVIG or  SCIG is weak and the infections occurred 
despite regular substitution. In this group of patients, especially with chronic inflammation 
(sinusitis, lymphocyte infiltrating pneumonia – LIP), bronchiectases, lung fibrosis and (in 
some cases) permanent leukopenia; the prophylaxis with antibiotics is suggested. The 3-4 
months’ periods of antibiotics or trimetoprim introduced in prophylactic dose help in 
control of infections and improve the patient’s comfort. The therapy with antibiotics is still a 
matter of discussion and approaches to this therapy varies depending of clinical centre, 
severity of cases. The recommendation for antibiotics prophylaxis is prevention of the 
endocarditis during invasive procedures [28]. 
4. Diagnostic procedures in celiac disease and inflammatory bowel 
diseases 
4.1. The standards of IBD and celiac disease diagnosis 
Standard of IBD diagnosis includes the clinical symptoms, laboratory tests (e.g. antibodies 
detection), imaging procedures (gastroscopy, colonoscopy, other radiological methods) and 
histological examination of jejunum biopsy [4,42-49]. The laboratory markers are helpful in 
early diagnosis preceding the onset of severe clinical symptoms in many patients. In last 
years the detection of antibodies associated with autoimmune process in gastrointestinal 
tract are commonly used as screening in risk group of children including 
immunodeficiencies (IgAD, CVID).  
4.1.1. The immunological markers 
The typical clinical symptoms of celiac disease (periods of diarrhea or constipation, 
abdominal pain, cramps, feeling of discomfort, low weight with difficulty to gain) in small 
children are noted in about 20% of all patients diagnosed as celiac [51]. The remaining 
patients demonstrate the results of jejunum functional disorders leading to sideropenic 
anemia, osteopenia, afts, enamel damage, delay of puberty, concentrations problems and 
hypoproteinemia or many others without direct association with gastrointestinal tract. The 
latent, silent or asymptomatic forms of celiac disease are diagnosed in older children, 
teenagers and adults. The familiar predisposition is associated with expression of HLA-DQ2 
and HLA-DQ8 determinants [43,48-50].  
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For celiac disease the serological assays include antibodies to: endomysium, 
transglutaminase and gliadin. The antibodies against gliadin (deamidated form – GAF) are 
tested in IgA and IgG class with indirect immunofluorescence in serum diluted 1:10 [52]. 
The sensitivity and specificity is declared as 100% in IgG class and 95-99% in IgA class [53]. 
The endomysial antibodies (EMA) are associated with reticulin-gliadin complex and 
transglutaminase as enzyme active in formation of this complex. Antibodies are tested with 
indirect immunofluorescence in serum (dilution 1:10) with tissue slides of monkey’s 
jejunum or smooth muscles (endomysium contains reticulin type 1 (R1) - basic antigen for 
endomysial antibodies). The serial dilution of serum is helpful in monitoring the results of 
Gluten Free Diet (GFD). The sensitivity and specificity of these antibodies in IgA class is up 
to 100% [48,50]. The test performed in IgG class is valid and clinically significant for IgAD 
patients. 
The discovery of role of tissue transglutaminase (tTg) in pathomechanism of celiac disease 
helped in understanding the induction of immune response to gliadin. This enzyme 
deamidated and/or transamidated gliadin proteins increasing their immunogenicity. 
Moreover, tTg is facilitating the formation of gliadin-reticulin complex and location of these 
complexes deposits on subepithelial basic membrane. The role of tTg in reduction of 
intestinal epithelial cell adhesion and in detachment of epithelium was described recently 
[2]. Antibodies against tTg are tested with ELISA commercially available kits for IgA and 
IgG class of immunoglobulins. The sensitivity of this test is 96%, the specificity – 98% 
[48,50].  The results of detection tTg antibodies are showed as optical density recalculated to 
standard curve. Results above 20 units are recognized as positive. High specificity of tTg 
antibodies and occurrence in level above 200 units seemed to be satisfactory for celiac 
disease diagnose without further biopsy of jejunum [50]. These antibodies are clinically 
significant in IgA class preferentially; with exception for IgAD when antibodies in IgG class 
are considered [52]. The introduction of GFD leads to decrease of antibodies production 
below detection level in 3-6 months in majority of patients [48,50]. Persistent high level of 
antibodies to tTg is observed in celiac disease refractory to GFD (RCD type I and RCD type 
II)[54]. Moreover, antibodies against tTg are observed in about 20% of patients with 
Leśniowski-Crohn’s disease. The clinical significance of these antibodies in Leśniowski-
Crohn’s disease is unknown. It might be thought; that the inflammation and lymphocytic 
infiltrates are spreading from region typical for celiac disease to another part of jejunum. 
However, the localization of Leśniowski-Crohn’s disease in other parts of gastrointestinal 
tract like esophagus or large bowel and presence of anti tTg antibodies is not supporting this 
idea [50].  
The antibodies against Saccharomyces cerevisiae (ASCA) antigens are observed in 60-80% of  
Leśniowski-Crohn’s disease patients [5,55]. Occurrence of these antibodies is explained by 
increased permeability of barrier between jejunum lumen:submucosal tissue and loss of 
precise selective role of this barrier. The direct contact between yeast and immunocompetent 
cells is possible and uncontrolled what stimulates production of antibodies. In healthy 
people this yeast is normally seen in distal region of jejunum (Bauchin’ valve) without the 
induction of antibodies production. ASCA in IgA class are clinically significant in patients 
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with normal IgA level as for IgAD patients the IgG class antibodies are assayed. For both 
class IgG and IgA the level above 20 RU/ml is considered as positive. However, comparison 
of ASCA in IgA and IgG in Leśniowski-Crohn’s patients showed ASCA in both 
immunoglobulin’s classes in majority of patients what suggested (according the author) that 
both IgA and IgG ASCA should be measured [5]. The diagnostic specificity of ASCA is 99% 
and sensitivity in Leśniowski-Crohn’s patients is 80%, positive predictive value - 88% [5]. 
The new tests (for ELISA) are based on eluated singular proteins of Saccharomyces cerevisiae 
membrane with the similar specificity for Leśniowski-Crohn’s disease.  
The immunofluorescence indirect test offers detection of antibodies to exocrine pancreas cells 
cytoplasm (PAB) and their products as useful for diagnosis of Leśniowski-Crohn’s disease 
[55]. Two distinct patterns were noted with the patients’ sera tested on human pancreas 
tissue. The following pancreatic autoantigens were identified;  glycoproteins expressed as 
glycosyl phosphoinositol (GP1) and membrane-anchored protein (GP2) [4]. GP2 is a 
glycosylated protein accounting for more than half of the zymogen granule membrane 
proteins in acinar cells. Recent studies showed the expression of GP2 is not limited to 
pancreatic acinar cells but is noted on epithelial cells follicle-associated or in Peyer’s patches 
too [4]. In the follicle-associated epithelial cells GP2 is restricted to M cells. These cells are 
located mainly in distal part of ileum being a site of original inflammation in reasonable 
percentage of patients with Leśniowski-Crohn’s disease [4]. The frequency of PAB antibodies 
in patients with Leśniowski-Crohn’s disease is rather low (14%-30%)[4,55-56] however, the 
specificity of this assay is 93%, positive predictive value is 77% and negative predictive value 
– 45% [55-56]. The clinical observations indicated the association of PAB with stricturing or 
penetrating form of the Leśniowski-Crohn’s disease [4] but this data were not supported by 
others. It means, that PAB are independent to disease activity, localization, clinical course and 
response to therapy with corticosteroids and/or immunosuppression [4,55]. 
The antinuclear (ANA), antimyeloperoxidase antibodies (pANCA) and against goblet cells 
(mucins are autoantigen, GAB) antibodies are commonly used for immunological diagnosis 
of ulcerative colitis (UC). Presence of these antibodies is detected with immunofluorescence 
and ELISA. The antibodies against neutrophils cytoplasmic antigens (ANCA) are recognized 
as cytoplasmic (proteins 3 - cANCA) and perinuclear (myeloperoxidase - pANCA) based on 
microscopic pattern [5,56]. pANCA prevalence in UC is estimated as 71.4%, in comparison to 
Leśniowski-Crohn’s patients – 2.3% and healthy control – 4.8% of positive seras. Comparison 
of IgA and IgG class of pANCA in group of 28 UC patients showed higher titer for IgA but in 
majority of patients pANCA were present in both classes of immunoglobulins.  The results of 
ELISA assay for ANCA with different eluated antigens showed lower percentage of patients 
with positive results than immunofluorescence. Probably the antigens used for ELISA are not 
covering all possible neutrophil cytoplasmic antigens reacting with patients serum [56]. The 
antigens identified as responsible for pANCA immune response in UC patients are localized 
not only in cytoplasm of neutrophils but also inside nucleus (histone 1, nonhistone 
chromosomal protein, high mobility group of proteins) [56].   
The presence of antibodies against goblet cells (GAB) is tested with immunofluorescence 
(normal jejunum slides) or ELISA. In study of 28 UC patients GAB was detected in 46.4% 
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[56] in both classes of immunoglobulins with much higher titer for antibodies in IgA class. 
The sensitivity of GAB is estimated as 46%, specificity – 100% predictive positive value – 
100% and predictive negative value – 73% [56]. Studies of reactivity of GAB with different 
tissue slides from gastrointestinal tract showed the best reactivity in appendix tissue [3]. The 
reaction with ileum, sigmoid and rectum tissue was from weak to strong with the tendency 
to resemble clinically affected intestinal segments [3].  
The antibodies to enterocytes were described as clinically significant marker for 
autoimmune enteropathy [43,57]. The detection of these antibodies with indirect 
immunofluorescence showed a linear pattern most frequently along the apex or brush 
border of enterocyte on frozen section of human small bowel. These antibodies are 
predominantly IgG class and have been reported to occur after the mucosal damage onset 
[57].  
4.1.2.The histology of jejunum in celiac disease and Leśniowski-Crohn’s disease 
The typical changes in celiac disease are classified according Marsh, Oberhuber and 
Corazza [48]. The classification according Marsh (4 types) is commonly used and number 
of intraepithelial lymphocytes (IEL), ratio crypts:villi heights, villi structure and height 
are basic parameters. In advanced stage (Marsh type 3) severe inflammation, flat villi and 
hyperplastic crypts are noted. In other classification e.g. Oberhuber the mucous of 
jejunum damage is divide into 8 stages including stage 0 of normal mucous structure, 
without changes. Classification proposed by Corazza is simplest and described only 3 
stages – grade A – normal architecture of mucous, grade B1 and grade B2 – with atrophic 
villi up to flat mucous. The problem of celiac disease diagnosis arises when patients with 
clinical symptoms and serology tests results suggesting celiac disease have no visible 
changes in histology of mucous membrane (Marsh type 0, Oberhuber type 0, Corazza 
grade A) [48,58]. For these patients, electron microscopy assay is useful for detection of 
submicroscopical changes of enterocytes which support celiac disease diagnosis or 
suggest the diagnosis of microscopic enteritis [48,51,57-59]. However, observations of 
patients with typical clinical symptoms of celiac disease without changes of mucous 
showed improvement on GFD supporting the clinical diagnosis of latent type of celiac 
disease [50]. 
The infiltrations and formation of new lymphoid nodules, increase of IEL number are 
typical for chronic inflammation of jejunum. Infiltration in celiac disease consists 
lymphocytes (T and B), plasma cells and some monocytes. Within the lymphocytes present 
in mucous membrane the cells with TCRγ/δ characteristic are observed. In Leśniowski-
Crohn’s disease the infiltration contains lymphocytes, monocytes, neutrophils and plasma 
cells. The similar pattern with increased number of neutrophils is noted in UC. The 
proportion between the cells within infiltrate is associated with profile of proinflammatory 
cytokines released locally and induction of antibodies production as effect of contact of 
antigen presenting cells (APC) with e.g. MPO from neutrophils or the nuclei debris after cell 
death in situ [45-46]. 
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The nature and function of T regulatory (Treg) subpopulation of T lymphocytes was 
extensively studied in relation to IBD. Natural Treg (CD4+/CD25+/FoxP3+) from  thymus 
and iTreg (inducible Treg) are involved in monitoring the immune response, maintaining 
the immune balance, prevention of excessive and potentially harmful immune activation 
within mucous of gastrointestinal tract [47,61-62]. The study of Treg lymphocytes 
(CD4/CD25/FoxP3) within the lamina propria patients with Leśniowski-Crohn’s disease and 
UC showed increased number of these cells; whereas the number in peripheral blood was 
decreased as compare to healthy people. It suggested central role of this population in local 
regulation of prolonged inflammatory process within jejunum wall [44]. 
Immunohistochemistry is the basic method for detection of Treg lymphocytes in biopsy 
specimens, the flow cytometry is used for assay of Treg number in peripheral blood. The 
immunohistochemistry is commonly used for analysis of proportion and characteristics of 
different cells within inflammation e.g. macrophages, T and B lymphocytes, plasma cells 
and others. This approach based on histopathology of jejunum helps to classify the 
subgroups of IBD patients. It will create specific “biological signature” unique to each 
patient so this patient can be treated with rational, individual therapy targeting the specific 
defect or aberrations underlying intestinal inflammatory pathway [47].   
5. Problems of gastrointestinal autoimmune diseases in children  
with PID 
5.1. Celiac disease in IgAD and CVID patients 
Celiac disease diagnosed as latent, silent or untypical form in children older than infants 
comprises about 80% of celiac patients. The clinical symptoms are discrete or absent so 
the diagnosis is often delayed. There have been more than 200 symptoms reported in 
association with gluten sensitivity [51]. The effects of jejunum dysfunction 
(malabsorption) presented as low level of iron resistant to oral therapy, vitamins, 
calcium, zinc and other minerals deficiency are suggesting celiac disease in children and 
teenagers [63]. The problem of celiac disease diagnosis in CVID and IgAD children lays 
in paucity and unspecificity of symptoms and overlapping with symptoms typical for 
IgAD or CVID with lack of IgA (e.g. abdomen pain, episodes of diarrhea, chronic 
diarrhea, food allergy).  
High prevalence of celiac disease in IgAD patients (10-20 times higher risk than in 
population) suggested the common genetic background for these two diseases. It was 
demonstrated that ancestral haplotype HLA-A1,Cw7,B8,DR3,DQ2 is important for 
association between IgA and celiac disease [6,12-13]. However, the observations of 
frequency of celiac disease within  IgAD population did not support this correlation because 
the observed frequency of celiac disease is still lower than expected based on genetic 
background [13]. Other hypothesis indicated that abnormal handling of gluten and gliadin 
in absence of IgA might induce the mucous damage and onset of clinical symptoms of celiac 
disease. The study of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand 
(APRIL) in patients with IgAD and celiac disease showed increased of both factors in IgAD 
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as compared to healthy persons but differences between IgAD with celiac disease and 
without celiac disease were below significance. Increase of APRIL level might be interpreted 
as part of the mechanism of compensation leading to overproduction of IgG and IgM [64]. 
The analysis of IEL TCRγ/δ showed highest level in IgAD with celiac disease,  increased 
number in IgAD - higher than control [60].  
The production of antibodies to gliadin, endomysium and to transglutaminase are 
preserved in IgAD patients but in IgG class. However, in some cases of IgAD the presence 
and high level of anti transglutaminase antibodies in IgA class is seen. In these cases the 
trace level of IgA (below detection in nephelometry) is enough to show antibodies to tTg 
with high sensitive technique of ELISA (personal observations). Within our 47 children with 
IgAD antibodies for celiac disease were noted in 11 patients (23%) – antibodies for gliadin – 
in 9 patients, for endomysium and for tTg in one patient each. Celiac disease was diagnosed 
based on anti tTg antibodies (in IgA and IgG class) in one patient without clinical 
symptoms. The histology of jejunum is typical for the celiac disease including cases 
diagnosed early with no changes (Marsh type 0) and similar to changes observed in children 
without IgAD. It is obvious, that in IgAD  plasma cells producing IgA are missing, although 
total number of plasma cells is preserved. In majority of IgAD patients the gluten-free diet 
(GFD) is effective [16].  
In CVID the problem of serological diagnosis of celiac diseases is more complex because of 
low production of antibodies and IgA deficiency in part of CVID patients. In consequence of 
these the possibility of serological diagnosis of autoimmune disease in CVID is excluded by 
many authors [9,13,37]. However, the permanent stimulation with autoantigens is leading to 
production of antibodies despite of decreased function of immune system. Level of 
autoantibodies is detectable but lower than in patients without immune deficiency [personal 
observation, 36]. In our study of 40 children with CVID antibodies for gliadin were noted in 
3 patients (7.5%), for endomysium and tTg in 2 patients followed with diagnosis of celiac 
disease. Algorithm for celiac disease diagnosis is shown in Table 2. In jejunum biopsy the 
mucous contains excess of IEL (mainly T), lymphoid aggregates, granulomas, crypts 
distortion. Within this group of patients the celiac disease is often refractory to GFD (RCD) 
leading to malabsorption syndrome and severe clinical conditions [20]. Poor response to 
GFD suggests the distinct pathogenesis of celiac disease with 2 forms recently recognized 
[13]. In type I of RCD the IEL expressed normally CD3 and CD8 determinants as well as 
polyclonal T-cell receptor (TCR) arrangement. In RCD type II the aberrant lymphocyte 
population is expanded with loss of surface expression of CD3 and CD8, intracellular 
presence of CD3 determination and monoclonal TCR arrangement. Type II of RCD is 
associated with poor prognosis, increased mortality due to progressing malabsorption 
syndrome and due to T-cell lymphoma in reasonable number of patients [54]. Therapy 
includes supplementation with proteins, vitamins and microelements, parenteral nutrition, 
probiotics, steroids (given intravenously in high dose) and antibiotics for bacterial 
overgrowth in jejunum [16]. The second line of therapy offers immunosuppression 
(azathioprine) and/or monoclonal antibodies against TNF (infliximab, etanercept, humira) in 
patients with  active, progressive disease [65]. 
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Table 2. Algorithm of the diagnostic procedures for celiac disease and IBD in CVID and IgAD patients 
5.2. Leśniowski-Crohn’s disease and UC in IgAD and CVID patients 
Chronic diarrhea is noted as a typical clinical symptom of gastrointestinal involvement seen 
in wide range of adult patients (10% - 50%) with CVID [13,16,18,20]. In children with CVID 
and IgAD the chronic diarrhea is much less frequent but data are based on relatively small 
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number of patients. IBD are sporadic in IgAD children with clinical course similar to 
children without IgAD. Within CVID patients IBD remain a significant problem in 19-32% of 
patients [20]. Moreover, IBD in patients with CVID is recognized as distinct form sharing 
histological features consistent more with lymphocytic colitis, collagenous colitis than 
classic IBD [13,37]. In patients, mainly adults, with Leśniowski-Crohn’s disease and CVID 
the formation of granuloma within jejunum wall is observed. Furthermore, the substitution 
of immunoglobulins does not inhibit and/or reverse symptoms of chronic colitis [13,15]. The 
different explanations are proposed but hypothesis that IgG from immunoglobulin 
preparations are not able to reach the lumen of intact jejunum particularly in CVID patients 
without IgA seemed to be interesting. Other possible explanations include Treg defects, T 
cell driven inflammation, different patterns of locally produced cytokines as compared to 
Leśniowski-Crohn’s disease in patients without CVID [13]. The special role of T 
lymphocytes in CVID patients with gastrointestinal symptoms was indicated by different 
histology of jejunum. Despite the lack of plasma cells in biopsy specimens as typical and 
characteristic; the villi flattening, increased number of IEL and lymphocytes in lamina 
propria, increased epithelial apoptosis were observed in CVID patients [13,15,20]. The study 
of cytokines produced locally in lamina propria showed decreased production of IL-23, IL-
17 and TNF in CVID patients with Leśniowski-Crohn’s disease as compare to patients 
without CVID, what suggest alternative pathway of inflammation [13]. 
Therapy of Leśniowski-Crohn’s disease in CVID is generally similar as for patients without 
immunodeficiency although inflammation in CVID might be more difficult to control. 
Immunosuppression (e.g.azathioprine, cyclosporine) is used when anti inflammatory drugs 
and steroids (rapidly metabolized budesonide) are without results and process of 
inflammation is still active. Induction of remission with anti cytokine monoclonal antibodies 
(infliximab, etanercept) is effective in CVID patients but the very careful monitoring of 
infections, particularly fungal, is necessary due to T cell defects [13]. 
The frequency of UC within CVID and IgAD patients is not known. The large study of 248 
patients with CVID including children and adults showed the UC only in 7 patients [19]. In 
this study ten patients was described as having a significant malabsorption but without 
specific gastrointestinal diagnosis what showed the problems of establishing the diagnosis 
in immune deficiency patients [19].  
5.3. Differential diagnosis – Collagenous sprue and autoimmune enteropathy 
The difficulties in diagnosis of celiac disease, poor response to GFD, IBD with different 
histology of jejunum seen in patients with CVID, IgAD and gastrointestinal symptoms 
suggested searching for other diseases overlapping clinical features. The collagenous sprue 
is severe malabsorptive disorder with histology similar to celiac disease. It is rare disorder 
characterized by small intestinal villi and crypts atrophy, increased IEL number, 
subepithelial collagen deposit entrapping cellular components of lamina propria [49]. The 
clinical and histological similarities (villi atrophy, poor response to GFD during one year) 
might suggest the refractory or poorly controlled celiac disease. However, in collagenous 
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sprue the  serological test and HLA-DQ2 or HLA-DQ8 are negative what indicate separate 
entity. The relation between celiac disease, refractory sprue and collagenous sprue is still a 
matter of discussion but collagenous sprue seemed to be a part of refractory sprue based 
on poor response to GFD [49]. In histology in collagenous sprue; the subepithelial collagen 
layer thicker than 12 μm, embedding small capillaries and lamina propria entrapping cells 
e.g. lymphocytes, fibroblasts are typical. These entrapped cellular elements are a 
mandatory criterion for this disease. Celiac disease is characterized by increased number of 
IEL whereas in collagenous sprue these lymphocytes are absent. The precise diagnosis is 
important because the collagenous sprue is progressing with high ratio of death due to 
malabsorption and malnutrition. The aggressive therapy includes steroids, 
immunosuppression and total parenteral nutrition. Up to now, the collagenous sprue was 
not observed in CVID and IgAD patients but the occurrence of RCD, progressing 
malabsorption syndrome might suggest existence of this disease within immune deficiency 
patients.  
The term of microscopic enteritis was used for patients with symptoms of malabsorption 
without prominent inflammation, villous effacement or ulceration seen in conventional 
light microscopy [59]. This observation may explain the co-existence of symptomatic gluten 
sensitivity, malabsorption and normally looking mucosa (Marsh 0) [48,58-59]. In patients 
with RCD the electron microscopy assay seemed to be useful for diagnosis of microscopic 
enteritis what helps to recognize celiac disease with mild or minimal mucosal 
abnormalities.  
The autoimmune enteropathy is not associated with celiac disease but represents 
heterogeneous entity consisting protracted diarrhea in young children with circulating 
antibodies. Affected patients appear to fall into 2 groups: with or without immune 
deficiency. The syndrome of intractable or protracted diarrhea of infancy was associated 
with high mortality. Now, the parenteral nutrition, symptomatic therapy of complications, 
improvement of diagnostic modalities has permitted prolonged survival of these children 
[57]. Immune deficiency seen in these patients were X-linked syndrome of neonatal diabetes 
with polyendocrinopathy, IPEX (Immunodysregulation, Polyendocrinopathy, Enteropathy, 
X-linked), T-cell defects, CVID and IgAD. The immunological tests showed a variety of 
antibodies but most important for diagnosis are antibodies against enterocyte circulating in 
patients serum. Other antibodies were typical for autoimmune disease of endocrine glands 
(anti thyroid peroxidase - TPO, Langerhan’s islet) and kidney, liver diseases (anti tubular 
basement membrane, antinuclear, anti-smooth muscles, liver-kidney antigen). Antigens for 
enterocyte antibodies were characterized as 50 kD and 75 kD proteins present in enterocyte 
cytoplasm. Diagnosis in neonate and infants with chronic severe diarrhea is based on small 
jejunum biopsy and immunological tests. The antibodies anti enterocyte are suggesting the 
autoimmune enteropathy. Symptomatic therapy include diet, parenteral nutrition, 
“immunological” therapy include steroids (but with no great success), immunosuppression 
with different drugs e.g. azathioprine, cyclophosphamide and cyclosporine. The second line 
of therapy offers tacrolimus with a good response. IPEX syndrome patient has been treated 
with hematopoietic stem cell transplantation [57]. 
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6. General remarks 
The diagnosis of IBD and celiac disease is based on clinical symptoms, laboratory tests and 
endoscopic procedures. Antibodies are the markers of these diseases despite that their role 
in pathomechanism of chronic inflammation is not fully recognized. The weak production of 
antibodies in response to vaccine antigens in humoral immunity deficiency seemed to be 
overestimated since the prolonged stimulation with antigens persistent in contact with 
immunocompetent cells induce production of antibodies. The antibodies detection used as 
screening is helpful in early diagnosis due to predictive value of these antibodies. From the 
other side, in patients with immunodeficiency clinical symptoms might be mild, unspecific 
and suggesting the association with basic disease (CVID or IgAD) not the concomitant 
autoimmunity. The high risk of autoimmune diseases in CVID and IgAD is an indication for 
antibodies screening in these patients but the results should be analyzed with caution. 
Patients with immunodeficiency are different in all aspects of their immune system function 
including response to infections, chronic inflammations, autoimmunity prevalence and high 
risk of tumours. The replacement of specific antibodies with substitution of 
immunoglobulin for CVID patients is covering only a small part from the complex defect in 
function of immune system. 
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